Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
LY3337641
DRUG
2 trials
Sponsors
Eli Lilly and Company
Conditions
Healthy
Rheumatoid Arthritis
Phase 1
A Study of LY3337641 in Japanese and Caucasian Healthy Participants
Completed
NCT03083561
Eli Lilly and Company
Healthy
Start: 2017-03-15
End: 2017-05-25
Updated: 2023-08-25
Phase 2
A Study of LY3337641 in Rheumatoid Arthritis
Terminated
NCT02628028
Eli Lilly and Company
Rheumatoid Arthritis
Start: 2016-08-22
End: 2018-08-15
Updated: 2019-10-09
Related Papers
Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection
Scientific Reports
2021-09-21
11 citations
Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study
The Journal of Rheumatology
2020-12-15
21 citations